-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In Western countries, about 1%-2% of people are receiving long-term anticoagulation therapy
DOAC has shown a positive benefit-risk balance in both clinical trials and clinical practice, but about 2%-3.
DOAC has shown a positive benefit-risk balance in both clinical trials and clinical practice, but about 2%-3.
Researchers systematically searched for studies of reversal drugs for the treatment of severe DOAC-related bleeding
thrombus
A total of 60 eligible studies were screened, covering 4735 patients who used 4-factor prothrombin complex concentrate (n=2688), idarucizumab (n=1111) or andexanet (n=936) to reverse DOAC-related severe bleeding
Mortality, thromboembolism rate and effective hemostasis rate of different reversal agents
Mortality, thromboembolism rate and effective hemostasis rate of different reversal agentsOverall, the mortality rate of the tested patients was 17.
The mortality of the tested patients was 17.
All-cause mortality in patients with or without effective hemostasis
All-cause mortality in patients with or without effective hemostasisThe effective hemostasis rate was 78.
The effective hemostasis rate was 78.
Although the effective hemostasis rate of reversal drugs is high, the mortality rate of anticoagulant patients after DOAC-related severe bleeding is still high
Original source:
Gómez-Outes Antonio,Alcubilla Pau,Calvo-Rojas Gonzalo et al.
Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants
in this message
